A Strategy of High-Dose Lenalidomide in Combination with Epigenetic Therapies for Relapsed or Refractory Acute Myeloid Leukaemia (AML)- Phase I.
Phase of Trial: Phase I
Latest Information Update: 22 Mar 2018
At a glance
- Drugs Lenalidomide (Primary) ; Azacitidine; Romidepsin
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- 20 Mar 2018 Status changed from recruiting to completed.
- 06 Jun 2017 Status changed from not yet recruiting to recruiting.
- 24 Mar 2012 New trial record